

Morepen Laboratories Limited
Statement of Audited Financial Results
For the Quarter and Year ended 31st March, 2013

		(Rs. in Lacs)					
		Standalone				Consolidated	
		Quarter ended			Year Ended		Year ended
		31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012	31.03.2013
		(Unaudited)			(Audited)		(Audited)
1(a)	Net Sales/Income from Operations (Net of Excise Duty)	7879	7180	6864	29578	26117	31834
(b)	Other Operating Income	222	241	822	757	833	758
	Total Income from Operations (Net)	8101	7421	7686	30335	26950	32592
2	Expenditure						
a)	Cost of Material Consumed	3515	3212	3480	13147	13242	13147
b)	Purchase of stock - in - trade	1526	1456	1769	5839	5041	6578
c)	Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	(30)	129	(297)	157	(507)	191
d)	Employee benefits expenses	893	883	865	3497	3265	3967
e)	Depreciation and Amortisation	1131	1155	1193	4574	4689	4580
f)	Power and Fuel	142	200	245	896	982	896
g)	Travelling Expenses	139	127	146	536	595	728
h)	Selling and Distribution Expenses	676	287	384	1559	1050	2051
i)	Other Expenses	497	404	335	1806	1519	1939
	Total Expenditure	8489	7853	8120	32011	29876	34077
3	Profit / (Loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	(388)	(432)	(434)	(1676)	(2926)	(1485)
4	Other Income /(Loss)	260	-	101	262	102	287
5	Profit / (Loss) from Ordinary activities before Finance Cost and Exceptional Items (3+4)	(128)	(432)	(333)	(1414)	(2824)	(1198)
6	Finance Cost	244	347	147	1161	796	1163
7	Profit / (Loss) from Ordinary activities after Finance Cost but before Exceptional Items (5-6)	(372)	(779)	(480)	(2575)	(3620)	(2361)
8	Exceptional Items - Income/(Expense)	-	-	-	-	-	-
9	Profit / (Loss) from Ordinary Activities before Tax (7-8)	(372)	(779)	(480)	(2575)	(3620)	(2361)
10	Tax Expense	-	-	-	-	-	0.5
11	Profit / (Loss) from Ordinary Activities after Tax (9-10)	(372)	(779)	(480)	(2575)	(3620)	(2361)
12	Extraordinary Items-Income/(Expense)	(26)	-	1204	308	1204	308
13	Net Profit / (Loss) for the period (11+12)	(398)	(779)	724	(2267)	(2416)	(2053)
14	Share of Minority Interest	-	-	-	-	-	(0.4)
15	Profit after Tax and Minority Interest	(398)	(779)	724	(2267)	(2416)	(2052)
16	Paid-up Equity Share Capital of Face Value of Rs.2/- each	8996	8996	8996	8996	8996	8996
17	Reserves excluding Revaluation reserves	-	-	-	-	14349	-
18	a) Earning Per Share before Extraordinary Items (in Rs.)* Basic & Diluted	(0.09)	(0.18)	(0.11)	(0.56)	(0.82)	(0.52)
	b) Earning Per Share after Extraordinary Items (in Rs.)* Basic & Diluted	(0.09)	(0.18)	0.16	(0.49)	(0.55)	(0.45)
A	PARTICULARS OF EQUITY SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	294454615	294454615	294454615	294454615	294454615	
	- Percentage of shareholding	65.46%	65.46%	65.46%	65.46%	65.46%	
2	Promoters and Promoter Group Shareholding						
a)	Pledged / Encumbered						
	- Number of Shares	610000	610000	610000	610000	610000	
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.39%	0.39%	0.39%	0.39%	0.39%	
	- Percentage of shares (as a % of the total share capital of the company)	0.14%	0.14%	0.14%	0.14%	0.14%	
b)	Non-encumbered						
	- Number of Shares	154761588	154761588	154761588	154761588	154761588	
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.61%	99.61%	99.61%	99.61%	99.61%	
	- Percentage of shares (as a % of the total share capital of the company)	34.40%	34.40%	34.40%	34.40%	34.40%	



B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed off during the year	Nil
	Remaining unresolved during the year	Nil
*After considering dividend on preference shares.		
Notes:		

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th May, 2013.
- The Company is exclusively engaged in the Pharmaceutical Business segment.
- The figures of the previous quarter/year, have been re-grouped/re-classified to conform to the current quarter/year's classification.
- Figures of the last quarter are balancing figures between audited figures in respect of full financial year and the published, year to date figures up to third quarter of
- Statement of Assets and Liabilities as required under Clause 41 of the Listing Agreement is as under :

Particulars		Standalone		(Rs. in Lacs)	
		(Audited)		(Audited)	
		Year ended		Year ended	
		31.03.2013	31.03.2012	31.03.2013	31.03.2012
A	EQUITY AND LIABILITIES				
1	Shareholders' Funds				
	(a) Share Capital	20961	20961	20961	20961
	(b) Reserves and Surplus	12081	14349	9027	11079
	Shareholders' Funds	33042	35310	29988	32040
2	Minority Interest			(43)	(42)
3	Non - Current Liabilities				
	(a) Long term borrowings	9449	11389	9465	11389
	(b) Other Long term liabilities	209	243	209	243
	(c) Long term provisions	678	560	717	573
	Non- current liabilities	10336	12192	10391	12205
4	Current Liabilities				
	(a) Trade Payables	5490	6359	5681	6498
	(b) Other current liabilities	5214	4320	4522	3896
	(c) Short term provisions	68	90	70	101
	Current liabilities	10772	10769	10273	10495
	TOTAL EQUITY AND LIABILITIES	54150	58271	50609	54698
B	ASSETS				
1	Non Current Assets				
	(a) Tangible Assets	33059	37357	33120	37392
	(b) Intangible Assets	32	-	7826	7794
	(b) Non - current Investments	12181	12181	387	387
	(c) Long term loans and advances	158	155	167	164
	Non- current assets	45430	49693	41500	45737
2	Current Assets				
	(a) Inventories	3675	3801	3705	3866
	(b) Trade receivables	3659	3313	3911	3515
	(c) Cash and cash equivalents	472	396	553	451
	(d) Short term loans and advances	601	842	623	900
	(e) Other current assets	313	226	317	229
	Current assets	8720	8578	9109	8961
	TOTAL ASSETS	54150	58271	50609	54698

Place: New Delhi
Date: 13.05.2013



For and on behalf of the Board

(Signature)

(Sushil Suri)
Chairman & Managing Director